Dr. Reddy's – Global Pharmaceutical Leader
Dr. Reddy's
Dr. Reddy's Laboratories Ltd. is an Indian pharmaceutical company founded in 1984 by Kallam Anji Reddy and headquartered in Hyderabad, Telangana. Its shares trade on India's NSE and BSE and, since 2001, on the New York Stock Exchange (NYSE).
The company started as a supplier of active pharmaceutical ingredients and today makes both active substances and finished medicines: generics, branded medicines and biosimilars. Its main therapeutic areas are oncology, diabetes, cardiovascular and infectious diseases. In India one of its best-known products is Omez (omeprazole), sold since the late 1980s.
Dr. Reddy's has built a biosimilars business. In 2007 it launched Reditux, a rituximab biosimilar, in India — about ten years before the first rituximab biosimilars were approved in Europe and the US. Other biosimilars followed, including bevacizumab.
The company manufactures in India and the United Kingdom. In 2006 Dr. Reddy's acquired the German generics maker betapharm. Its medicines are sold in India, the US, Europe and other markets.
Unifarm carries Dr. Reddy's oncology medicines: Reditux 100 and Reditux 500 (rituximab) and Versavo 100 and Versavo 400 (bevacizumab).